Vertex announces u.s. fda approval for trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include additional non-f508del trikafta-responsive variants

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced the u.s. food and drug administration (fda) has approved the expanded use of trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (cf) ages 2 and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene or a mutation that is responsive to trikafta based on clinical and/or in vitro data. in ad.
VRTX Ratings Summary
VRTX Quant Ranking